白蛋白结合型紫杉醇治疗紫杉类耐药的复发性卵巢癌的临床疗效

发布时间：2019-05-10 23:05

【摘要】：目的:观察白蛋白结合型紫杉醇在既往紫杉类(紫杉醇、多西紫杉醇)耐药的复发性卵巢癌治疗中的近期疗效和安全性。方法:选取32例既往使用紫杉类药物治疗失败的复发性卵巢癌患者予以白蛋白结合型紫杉醇方案治疗。白蛋白结合型紫杉醇每周期计量为260mg/m~2,静脉滴注30min(用药前不予抗过敏处理),合并抗肿瘤药按常规方法给药,21天为一周期,每2个周期评估疗效及毒副反应。结果:32例患者全部可评估疗效。完全缓解(CR)0例(0.0%),部分缓解(PR)10例(31.3%),疾病稳定(SD)15例(46.9%),疾病进展(PD)7例(21.9%),客观有效率(ORR)31.3%,临床获益率(CBR)78.1%,中位无疾病进展时间(PFS)为3.8个月。主要毒副反应为高血压、骨髓抑制、恶心、呕吐、脱发、四肢麻木、肌肉关节酸痛,无化疗相关死亡病例。结论:白蛋白结合型紫杉醇治疗既往紫杉类耐药的复发性卵巢癌有较好的近期疗效,毒副反应可耐受。
[Abstract]:Objective: to observe the short-term efficacy and safety of albumin-binding paclitaxel in the treatment of recurrent ovarian cancer with Taxol (paclitaxel) resistance. Methods: 32 patients with recurrent ovarian cancer who failed to be treated with yew drugs were treated with albumin combined paclitaxel regimen. The dose of albumin-binding paclitaxel was 260 mg / kg per cycle, 30min was given intravenously, and anti-tumor drugs were given according to the routine method for 21 days. The efficacy and side effects were evaluated every two cycles. Results: all the 32 patients could evaluate the curative effect. Complete remission of (CR) was found in 0 cases (0.0%), partial remission of (PR) in 10 cases (31.3%), disease stable (SD) in 15 cases (46.9%), disease progression in 7 cases (21.9%), objective response rate of (ORR) in 31.3%, and disease progression in 7 cases (21.9%). The clinical benefit rate was 78.1%, and the median disease-free time (PFS) was 3.8 months. The main side effects were hypertension, myelosuppression, nausea, vomiting, alopecia, numbness of limbs, muscle and joint soreness, and no chemotherapy-related death. Conclusion: albumin-binding paclitaxel has a good short-term efficacy and side effects in the treatment of recurrent ovarian cancer with yew resistance.
【作者单位】：哈尔滨医科大学附属肿瘤医院妇科;
【基金】：黑龙江省教育厅科学技术研究项目(编号:12531386)
【分类号】：R737.31

【相似文献】